Sequent Scientific
214.79
-1.65(-0.76%)
Market Cap₹5,405.20 Cr
PE Ratio132.22
IndustryHealthcare
Company Performance:
1D-0.76%
1M+6.02%
6M+40.68%
1Y-3.40%
5Y+40.11%
View Company Insightsright
More news about Sequent Scientific
08Aug 25
SeQuent Scientific Reports Strong Q1 Results with 13% Revenue Growth and 94% PAT Surge
Sequent Scientific, an animal health sector company, reported robust Q1 financial results. Consolidated revenue increased 13.1% year-on-year to ₹4,414.00 million, while adjusted EBITDA rose 24.7% to ₹602.00 million. Net profit surged 93.7% to ₹176.00 million, with EBITDA margins improving by 120 basis points to 13.6%. The formulations business showed growth across Europe and emerging markets, while the API segment grew 14%. The company's merger with Viyash Life Sciences is progressing, with regulatory requirements expected to be completed in the coming months.
28Jul 25
Sequent Scientific Sets Stage for Major Amalgamation with Shareholder and Creditor Meetings
Sequent Scientific Limited (SSL) has scheduled meetings on August 30, 2025, for equity shareholders and unsecured trade creditors to approve a Composite Scheme of Amalgamation involving SSL and nine other companies. The meetings will be held via video conferencing, with e-voting available from August 26 to 29, 2025. The amalgamation includes companies such as Symed Labs Limited, Vandana Life Sciences Private Limited, and Sequent Research Limited. This move complies with NCLT orders and SEBI regulations, potentially reshaping SSL's corporate structure in the life sciences industry.
29May 25
Sequent Scientific's Merger with Viyash Advances: Stock Exchange Approvals Secured
Sequent Scientific has obtained approvals from stock exchanges for its proposed merger with Viyash, marking a significant step in the consolidation process. The company has subsequently filed for clearance with the National Company Law Tribunal (NCLT), a crucial step for legal consolidation. This merger is expected to enhance operational synergies, expand market presence, and strengthen the combined entity's position in the pharmaceutical sector. The focus now shifts to obtaining NCLT clearance as the merger proceedings continue.
20May 25
SeQuent Scientific Reports ₹44.3 Crore Net Profit in Recent Financial Year
SeQuent Scientific, a leading animal health company, has reported a significant financial turnaround. The company posted a net profit of ₹44.3 crore for the recent financial year, recovering from a ₹54.6 crore loss in the previous year. Revenue grew by 13.3% to ₹1551.40 crore. In the most recent quarter, net profit was ₹16.3 crore, with revenue increasing 11.11% year-over-year to ₹400.00 crore. EBITDA rose 43.0% to ₹46.20 crore, with the EBITDA margin expanding to 11.51%. Despite strong performance, no dividend was declared.
Sequent Scientific
214.79
-1.65
(-0.76%)
1 Year Returns:-3.40%
Industry Peers
Sun Pharmaceutical
1,691.40
(+0.33%)
Divis Laboratories
6,656.50
(-3.30%)
Cipla
1,505.70
(+0.28%)
Torrent Pharmaceuticals
3,580.00
(+0.75%)
Dr Reddys Laboratories
1,205.40
(+0.02%)
Zydus Life Science
944.10
(+0.79%)
Mankind Pharma
2,261.80
(-2.05%)
Lupin
1,971.80
(+0.83%)
Alkem Laboratories
5,668.50
(+0.44%)
Aurobindo Pharma
1,123.80
(-1.47%)